The following table presents unaudited quarterly consolidated operating results for each of our last ten quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements (in millions, except per share amounts).



Year Ended December 31, 2016	First Quarter ⁽²⁾			Second Quarter ⁽³⁾			Third Quarter ⁽⁴⁾			Fourth Quarter ⁽⁵⁾
	Restated			Restated			Restated			Fourth Quarter ⁽⁵⁾
Net sales	$	1,347.3		$	1,340.5		$	1,261.6		$	1,331.2
Gross profit	$	533.1		$	546.5		$	484.5		$	487.7
Tysabri^® royalty stream - change in fair value	$	204.4		$	910.8		$	377.4		$	1,115.6
Net loss	$	(529.2	)	$	(534.3	)	$	(1,590.2	)	$	(1,359.1	)
Loss per share⁽¹⁾:
Basic	$	(3.70	)	$	(3.73	)	$	(11.10	)	$	(9.48	)
Diluted	$	(3.70	)	$	(3.73	)	$	(11.10	)	$	(9.48	)
Weighted average shares outstanding
Basic	143.2			143.2			143.3			143.4
Diluted	143.2			143.2			143.3			143.4

⁽¹⁾The sum of individual per share amounts may not equal due to rounding.


⁽²⁾	Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.


⁽³⁾	Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.


⁽⁴⁾	Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.


⁽⁵⁾	Includes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million.



	September 26, 2015 ⁽²⁾			December 31, 2015 ⁽³⁾
Six Months Ended December 31, 2015	Restated			Restated
Net sales	$	1,273.1		$	1,359.1
Gross profit	$	535.2		$	543.7
Tysabri^®royalty stream - change in fair value	$	(173.8	)	$	116.6
Net income (loss)	$	260.9		$	(218.4	)
Income (loss) per share⁽¹⁾:
Basic	$	1.78		$	(1.51	)
Diluted	$	1.78		$	(1.51	)
Weighted-average shares outstanding
Basic	146.3			144.9
Diluted	146.9			144.9

⁽¹⁾ The sum of individual per share amounts may not equal due to rounding.

⁽²⁾ Includes Mylan defense-related fees of $15.6 million.


⁽³⁾	Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.



	First Quarter		Second Quarter⁽²⁾			Third Quarter⁽³⁾			Fourth Quarter⁽⁴⁾
Year Ended June 27, 2015	Restated		Restated			Restated			Restated
Net sales	$	859.6	$	985.1		$	967.2		$	1,415.2
Gross profit	$	304.1	$	369.7		$	369.4		$	601.0
Tysabri^® royalty stream - change in fair value	$	58.9	$	(105.8	)	$	(100.8	)	$	69.2
Net income (loss)	$	29.4	$	151.1		$	(22.2	)	$	(22.2	)
Income (loss) per share⁽¹⁾:
Basic	$	0.22	$	1.11		$	(0.16	)	$	(0.15	)
Diluted	$	0.22	$	1.10		$	(0.16	)	$	(0.15	)
Weighted-average shares outstanding
Basic	133.9		136.3			140.8			146.3
Diluted	134.4		136.8			140.8			146.3

⁽¹⁾ The sum of individual per share amounts may not equal due to rounding.


⁽²⁾	Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.


⁽³⁾	Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.


⁽⁴⁾	Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.